β-Thalassemia: Expert Insights on New Therapies for an Old Disease

β-Thalassemia: Expert Insights on New Therapies for an Old Disease (December 2019)

Friday, December 6, 2019
Webinar -- 1:00 PM ET
http://www.clinicaloptions.com/2019OrlandoBetaTJoin

Agenda

1:00 PM – 1:10 PM Welcome and Introduction – Maria Domenica Cappellini, MD

1:10 PM – 2:00 PM Current Management of β-Thalassemia – Sujit Sheth, MD

2:00 PM – 2:50 PM Emerging Biological Therapies on the Horizon for β-Thalassemia – Maria Domenica Cappellini, MD

2:50 PM – 3:40 PM The Promise of Gene Therapy in β-Thalassemia – Janet L. Kwiatkowski, MD, MSCE

3:40 PM – 4:00 PM Panel Discussion and Audience Question and Answer Session

Faculty

Program Director
Maria Domenica Cappellini, MD

Professor of Internal Medicine
Chief, Internal Medicine Unit
Internal Medicine Department
University of Milan-Fondazione IRCCS Ca' Granda Policlinico Hospital
Milan, Italy

Faculty
Janet Kwiatkowski, MD, MSCE

Professor of Pediatrics
Director of Thalassemia Program

Division of Hematology
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

Faculty
Sujit Sheth, MD

Professor
Department of Pediatrics
Weill Cornell Medicine
New York, New York

Goal Statement
The goal of this activity is to improve participants’ knowledge of and competence in using novel curative and noncurative therapeutic options for patients with β-thalassemia.

Target Audience
This program is intended for hematologists and other clinicians involved in the management of patients with β-thalassemia.

Learning Objectives

  • Evaluate the medical need for novel therapeutic strategies for the management of β-thalassemia
  • Describe the safety and efficacy evidence for novel approaches to reducing transfusion dependence through the use of erythroid maturation agents
  • Explain the mechanism of action of gene therapy as a curative approach to β-thalassemia
  • Examine key efficacy and safety data on emerging gene therapy strategies and their potential role in the management of patients with β-thalassemia
  • Identify patients with β-thalassemia who are candidates for ongoing clinical trials

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.